Targeting Tumorigenic Coactivators in the PI3K/AKT Signaling Pathway: A Novel Approach for Cancer Treatment

Area of Science:

• Oncology
• Molecular Biology
• Signaling Pathways

Background:

• Persistent activation of the PI3K/AKT signaling pathway is a hallmark of many cancers.
• This pathway's hyperactivation drives tumor growth and contributes to resistance against therapies.

Purpose of the Study:

• To explore upstream coactivators driving PI3K/AKT pathway activation in cancer.
• To investigate the roles of TMEPAI, SALL4, TCL1B, and TGF-β in tumorigenesis.
• To summarize mechanistic insights and therapeutic opportunities targeting these coactivators.

Main Methods:

• Comprehensive literature review of four PI3K/AKT coactivators: TMEPAI, SALL4, TCL1B, and TGF-β.
• Analysis of their mechanistic insights and signaling interactions.
• Summary of emerging therapeutic strategies.

Main Results:

• Each coactivator (TMEPAI, SALL4, TCL1B, TGF-β) distinctly contributes to PI3K/AKT hyperactivation and cancer progression.
• Mechanisms include downregulating negative regulators or directly enhancing AKT activation.
• Emerging therapies include gene silencing, small-molecule inhibitors, and peptide-based interventions.

Conclusions:

• Multiple molecular classes converge on the PI3K/AKT pathway, driving cancer progression.
• Targeting these coactivators presents promising avenues for novel cancer therapies.
• Future research should address challenges like drug specificity, toxicity, and resistance.